I Holland's MF80 Automated Punch Polisher
: I Holland’s MF80 Automated Punch Polisher fits seamlessly into the tool room environment ensuring optimum GMP compliance. Increased holder capacity allows more punches to be polished per cycle.
I Holland, the leading specialist manufacturer of tablet tooling for the pharmaceutical and nutraceutical industries has launched the innovative MF80 automated punch polisher, which offers a large capacity for increased polishing per cycle.
MF80 has been designed to increase polishing volume, thanks to the product’s 80 litre drum which can hold up to 17 B or 12 D punches per holder, giving a maximum of 85 B or 60 D punches per polishing cycle.
It offers a solution to overcoming tooling problems like sticking and corrosion, and will polish dull and discoloured punches to a micro fine, high quality finish, by using a drag finishing process. Punches are automatically rotated through media and polishing paste, saving time over manual polishing operations and ensuring a consistent result.
The importance of maintaining tools is essential to extending the life of tablet tooling and by using a machine like the MF80 as part of the I Holland 7 Step PharmaCare®process, a professional maintenance and storage programme, tooling life will be extended.
The new automated punch polisher offers a smooth operation, whilst improving efficiency in the tablet press resulting in a quality tablet. Operated via touchscreen software and available in several languages, the MF80 is now used by manufacturers’ world-wide.
Contact Details:
I Holland
Website:www.iholland.co.ukE-mail: info@iholland.co.uk
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of On-Demand Manufacturing and Derisking in Accelerating Early Clinical Trial Success
June 4th 2025Small pharmaceutical companies are constantly seeking innovative solutions to streamline early clinical trials. Adaptive clinical trials offer important benefits to sponsors and patients, both from a commercial and ethical standpoint. These trials offer flexibility and efficiency, especially in the early stages, where trial protocols can be adjusted based on interim data, such as introducing new doses or modifying participant sample size. However, adjusting manufacturing demand during an adaptive trial can be complicated, and strict regulatory requirements present significant challenges. On-demand manufacturing provides a robust solution, allowing for real-time supply and demand adjustments and improved trial flexibility. This paper explores how on-demand manufacturing meets the operational needs of adaptive trials and aligns with regulatory expectations.
